Ratan Capital Management LP Invests $1.54 Million in Solventum Corporation $SOLV

Key Points

• Ratan Capital Management acquired 20,000 Solventum shares worth approximately $1.54 million, making the stock its 29th-largest holding and about 0.5% of its portfolio.
• Analyst sentiment remains positive, with eight Buy ratings, four Holds and one Sell; Solventum has a “Moderate Buy” consensus rating and a $91.64 average price target.
• Solventum exceeded quarterly expectations, reporting $2.55 in EPS versus the $1.91 consensus and $2.21 billion in revenue. Shares opened at $91.02, near the company’s 52-week high of $92.71.

Ratan Capital Management LP acquired a new position in Solventum Corporation (NYSE:SOLV - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 20,000 shares of the company's stock, valued at approximately $1,543,000. Solventum accounts for about 0.5% of Ratan Capital Management LP's portfolio, making the stock its 29th biggest position.

Other institutional investors have also added to or reduced their stakes in the company. CrossGen Wealth LLC bought a new position in Solventum during the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum in the 3rd quarter worth approximately $25,000. Clearstead Trust LLC boosted its stake in shares of Solventum by 61.0% in the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company's stock valued at $26,000 after purchasing an additional 150 shares during the last quarter. CYBER HORNET ETFs LLC bought a new stake in shares of Solventum in the 2nd quarter valued at $28,000. Finally, Modus Advisors LLC acquired a new stake in shares of Solventum during the fourth quarter worth $30,000.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on SOLV shares. BMO Capital Markets started coverage on shares of Solventum in a research note on Wednesday, July 8th. They set a "market perform" rating and a $81.00 target price for the company. Wall Street Zen cut shares of Solventum from a "buy" rating to a "hold" rating in a research report on Saturday, August 22nd. KeyCorp increased their price target on Solventum from $93.00 to $102.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Wedbush lifted their price objective on Solventum from $94.00 to $101.00 and gave the stock an "outperform" rating in a research report on Thursday, August 6th. Finally, UBS Group boosted their price objective on Solventum from $95.00 to $101.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $91.64.

Solventum Stock Performance

Shares of SOLV stock opened at $91.02 on Friday. The firm has a 50 day moving average of $82.46 and a 200-day moving average of $75.55. The company has a market cap of $15.49 billion, a price-to-earnings ratio of 11.13, a price-to-earnings-growth ratio of 1.17 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $92.71.

Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. Solventum's quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, equities analysts forecast that Solventum Corporation will post 7.22 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source